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Abstract 
Myocardial ischemia (MI) remains one of the leading causes of death worldwide. 
Angiogenic therapy with the vascular endothelial growth factor (VEGF) is a promising 
strategy to overcome hypoxia and its consequences. However, from the clinical data it is 
clear that fulfillment of the potential of VEGF warrants a better delivery strategy. On 
the other hand, the compelling evidences of the role of oxidative stress in diseases like 
MI encourage the use of antioxidant agents. Coenzyme Q10 (CoQ10) due to its role in the 
electron transport chain in the mitochondria seems to be a good candidate to manage MI 
but is associated with poor biopharmaceutical properties seeking better delivery 
approaches.  
The female Sprague Dawley rats were induced MI and were followed up with VEGF 
microparticles intramyocardially and CoQ10 nanoparticles orally or their combination 
with appropriate controls. Cardiac function was assessed by measuring ejection fraction 
before and after three months of therapy. 
Results demonstrate significant improvement in the ejection fraction after three months 
with both treatment forms individually; however the combination therapy failed to offer 
any synergism. In conclusion, VEGF microparticles and CoQ10 nanoparticles can be 
considered as promising strategies for managing MI.  
 
Keywords: VEGF, CoQ10, protein delivery, angiogenesis, tissue engineering, 
myocardial ischemia.  
Abbreviations:  
CVD: Cardiovascular disease 
VEGF: Vascular endothelial growth factor 
CoQ10: Coenzyme Q10
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DDS: Drug delivery system 
MP: Microparticle 
NP: Nanoparticle 
TROMS: Total recirculation one machine system 
PEG: Poly (ethylene glycol) 
PLGA: Poly (lactic-co-glycolic) acid 
PVA: Poly (vinyl alcohol) 
DMSO: Dimethylsulfoxide 
DCM: Dichloromethane 
HUVEC: Human umbilical vein endothelial cell 
EF: Ejection Fraction 
MI: Myocardial ischemia 
 
1. Introduction 
Cardiovascular diseases (CVD) continue being the leading cause of death worldwide in 
spite of increasing efforts to improve its management. World Health Organization 
estimates that by 2030 almost 25 million of all global deaths will be due to CVD. 
Within this group of disorders coronary heart disease and stroke will be the main cause. 
Both, myocardial ischemia and strokes are principally caused by the accumulation of an 
atherosclerotic plaque in an artery. In the heart tissue ischemia is followed by a complex 
process involving cells (Tucka et al., 2012), growth factors (GFs) (Gullestad et al., 
2012) and the extracellular matrix (Eckhouse and Spinale, 2012) that ends in the 
remodeling of the ventricle and heart failure.  
To avoid consequences of ischemia in the heart the idea of growing new blood vessel 
for increased supply blood and better heart function has been proposed (Mitsos et al., 
 3
2012). Vascular endothelial growth factor (VEGF) is endogenously released by cells 
after myocardial ischemia and its supplementation to help damaged tissue to efficiently 
complete vessel formation has been studied in depth (Wang et al., 2013, Formiga et al., 
2012). However, one of the major drawbacks of the therapy with GFs is its short half-
life, being good candidates to be incorporated into drug delivery systems that protect 
them from degradation while extending its performace by sustaining the release (Simon-
Yarza et al., 2012).  
Cardioprotection is more of a prophylactic measure to prevent or reduce myocardial 
damage and the use of antioxidants is gaining importance in this area (Burgoyne et al., 
2012, Maksimenko and Vavaev, 2012). Coenzyme Q10 (CoQ10), also known as 
ubiquinone, is a molecule that is responsible of the electron flow between complexes 
one and two with complex three in the electron transport chain (Sohal and Forster, 
2007). It is well known because of its antioxidant role in several pathologies and it has 
been administered in coronary artery disease due to its cardioprotective role (Littarru et 
al., 2011). It is used as adjunctive therapy combined with different drugs and/or clinical 
interventions (Pepe et al., 2007; Fotino et al., 2012). However, CoQ10 is still seeking 
solutions to overcome poor oral bioavailability problems (Beg et al., 2010). Strategies to 
improve gastrointestinal absorption have been previously studied with proven success in 
several pathologies (Ankola et al., 2007; Ratnam et al., 2009). 
The present study is an attempt to compare the efficacy of particulate forms of VEGF 
and CoQ10 and to investigate the possibilities of synergism of the respective 
combination in an animal model of MI.  
2. Materials and methods 
2.1 Chemicals 
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Human recombinant VEGF was from R&D Systems (Minneapolis, MN, USA) and 
CoQ10 was a gift from Tishcon Corp. (Westbury, NY). All chemicals were provided by 
Sigma-Aldrich (Barcelona, Spain), organic solvents by Panreac Quimica S. A. 
(Barcelona, Spain) except high-performance liquid chromatography-grade methanol, 
ethanol, and acetonitrile that were procured from J.T. Baker (now Avantor Performance 
materials, Phillipsburg, NJ). Polymers were purchased from Boehringer-Ingelheim 
(Ingelheim, Germany) and western blot reagents from BioRad, unless specified in the 
text. Rabbit polyclonal anti-human VEGF-A (clone A-20, sc-152) was supplied by 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). ECL™ anti-Rabbit IgG horseradish 
peroxidase-linked whole antibody was from Amersham Biosciences (Buckinghamshire, 
UK). Human umbilical venous endothelial cells (HUVECs) were obtained from 
umbilical cords from donors, after informed consent according to the guidelines of the 
Committee on the Use of Human Subjects in Research at the Clinic Universidad de 
Navarra. Components of cell culture media were purchased by ATCC-LGC. CellTiter 
96® AQueous One Solution Cell Proliferation Assay (MTS) was provided by Promega. 
Isofluorane employed for animal anaesthesia was IsoFlo® from Abbot Laboratories 
S.A. and sutures were from Ethicon (Johnson & Johnson, Brussels).  
2.2 Preparation of Coenzyme Q10 encapsulated nanoparticles  
CoQ10 encapsulated nanoparticles were prepared as reported previously in our 
laboratory (Ratnam et al., 2011) however with slight modifications that in the current 
study large scale batches were made instead of lab scale preparations (50 mg) The 
procedure in brief goes as follows: PLGA (Resomer RG 50:50 H; intrinsic viscosity 
0.32-0.44 dl/g) (3 g) is dissolved in 150 ml of ethyl acetate under stirring and CoQ10 
(1.5 g) was added to the polymer solution and stirring continued for one hour. In a 
separate bottle, PVA (PVA) (Mol. Wt. 30,000-70,000) (3 g) was dissolved in 300 ml of 
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distilled water over a period of one hour. The CoQ10 containing polymer solution (25ml 
x 6 lots) was emulsified into (50 ml x 6 lots) of PVA solution over 30 min stirring (1000 
rpm). This emulsion is then homogenized for 30 min at 15000 rpm and added to 250 ml 
of distilled water and left for overnight stirring to ensure complete evaporation of ethyl 
acetate. The suspension was centrifuged at 14,000 g for 30 min and the pellet collected 
was then re-suspended in 4 ml of distilled water either by vortex or occasionally probe 
sonication. Particle size was measured using zeta sizer (Malvern Zata sizer, UK) before 
and after centrifugation. The suspension was divided into two equal parts (2 ml each) in 
a 5 ml vial and 5 % (w/v) trehalose was added and lyophilised using a bench top freeze 
dryer (Martin Christ, Germany) using the following condition 8 h freezing (-80 ºC and 
safety pressure 1.650); followed by main drying for 48 h (-50 ºC, 0.0035 mBar vacuum 
and safety pressure 1.650) and final drying of 12 h +20 ºC 0.0035 mBar vacuum and 
safety pressure 1.650). The freeze dried particles were characterized for particle size and 
CoQ10 entrapment using reported HPLC method in our laboratory (Ratnam et al., 2011). 
Nanoparticles without CoQ10 (NL-NPs) were prepared following similar procedure 
without adding CoQ10 to the preparation. 
2.3 VEGF Microparticle preparation and characterization 
VEGF microparticles (VEGF-MPs) were prepared by double emulsion solvent 
evaporation method, as previously described (Simon-Yarza et al., 2013). Briefly, VEGF 
(50 µg) was included in the aqueous solution. On the other hand, 25 mg PLGA 
Resomer® RG 503 and 25 mg poly [(d,l-lactide-co-glycolide)-co-PEG] diblock 
Resomer® RGP d 50105 were dissolved in a mixture of DCM and Acetone (3:1). By 
using TROMS® technology (Garbayo et al., 2008; Formiga et al., 2010; Simon-Yarza 
et al., 2013), organic phase was incorporated into the inner aqueous phase to form the 
first emulsion, that was then incorporated into the PVA 0.5 % external aqueous phase, 
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to form the multiple emulsion. Particles were then formed by solvent evaporation during 
3 hours under constant stirring (300 rpm). Freeze-drying was employed to store 
particles until its use.  
Non-loaded microparticles (NL-MPs) to be used in the control groups were prepared in 
the same way without VEGF.  
Particle size was determined by laser diffractometry using a Mastersizer-S® (Malvern 
Instruments, Malvern, UK). Sample preparation was done by dispersing 3 ml of particle 
suspension into the small volume dispersion unit. To do the measurements Mastersizer-
s v2.19 software was used.  
Microparticle (MP) residual PVA content was studied by a colorimetric assay based on 
the reaction occurring between two adjacent hydroxyl groups of PVA and iodine 
molecule leading to the formation of a colored complex (Joshi et al., 1979). 
Measurements were performed in triplicate. 
To determine MP protein content 0.5 mg of loaded MPs were dissolved in 20 µl DMSO. 
Incubation with rabbit antihuman VEGF-A antibody (1:2000) lasted 2.5 h at RT. 
Horseradish peroxidase (HRP)-conjugated donkey anti-rabbit IgG antibody (1 h, RT, 
1:2000) was performed to detect antibody binding. Chemiluminescence detection was 
performed using LumiLight Plus western blotting substrate (Roche Diagnostics, 
Mannheim, Germany). The VEGF signal was quantified by densitometry using the 
Quantity One software (Bio-Rad Laboratories, Inc., Munich, Germany). 
For the in vitro release studies, 1 mg of VEGF-MPs were introduced in 1.5 ml tubes and 
dispersed in 300 µl PBS pH 7.4 with 0.02 % (w/v) sodium azide, incorporated as a 
bacteriostatic agent. Samples were incubated under orbital shaking at 37 ºC. At different 
time points, tubes were centrifuged (20,000 g, 10 min) and 60 µl of supernatant were 
removed for its analysis and replaced with the same volume of fresh release medium. 
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VEGF concentration in the supernatants was measured by western blot, using the 
protocol described in the previous section. Release profile was expressed as cumulative 
release during a period of time. All measurements were done in triplicate.  
2.4 Bioactivity of encapsulated VEGF 
To confirm that protein bioactivity was not affected during the microencapsulation 
process a proliferation cell culture assay was done (Hervé et al., 2005). HUVECs were 
obtained from human umbilical cords. Tissue digestion was done with 0.1 % 
collagenase II (Jaffe et al., 1973). Afterwards, cells were expanded in F12K medium 
(ATCC 30-2004) supplemented with 30 µg/ml endothelial cell growth supplement 
(ECGS, BD Biosciences), 10 % fetal bovine serum, 1 % sodium heparin and 1 % 
penicillin/streptomycin. 
For the proliferation study, cells were plated into 96-well culture plates (3×103 
cells/well). 12 h after seeding, cells were treated with 10 ng/ml of non-encapsulated 
VEGF or released VEGF from the MPs. After 72 h incubation time under normal 
culture conditions proliferation in each group was measured using MTS assay. 
2.5 In vivo experiments  
The experiments were conducted according to the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (NIH Publication 
No. 85-23, revised 1996). All animal procedures were approved by the University of 
Navarra Institutional Committee on Care and Use of Laboratory Animals as well as the 
European Community Council Directive Ref. 86/609/EEC.  
Female Sprague-Dawley rats (40) weighing approximately 240-260 g were provided by 
Harlan-IBERICS (Barcelona, Spain) and housed in conventional animal quarters. 
Environment was controlled (12 h light/dark cycle at 21°C) and all animals received a 
standard diet and water ad libitum.  
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2.5.1 Animal model 
Anesthesia was firstly induced in an induction chamber with 2 % Isoflurane. Then 
animals underwent tracheal intubation for ventilation that was maintained during the 
procedure (10-15 ml/kg, 80-90 respiratory rate). Anesthesia was maintained with 0.5 % 
isoflurane during the surgery. Before the heart operation, animals received analgesic 
drug ketoprofen 5 mg/Kg subcutaneously and fentanyl 0.15 mg/kg intraperitoneally. 
The surgical approach consisted of a left thoracotomy through the fourth intercostal 
space. After pericardium was opened, left anterior descending (LAD) coronary artery 
was blocked 2–3 mm distal from its origin with a ligature with an 7/0 polypropylene 
suture. The chest was closed in layers using resorbable suture Vicryl® 4/0 and rats were 
allowed to recover. Surgical procedure total time was 30 minutes.  Only those rats with 
an EF equal or below 55% (as determined by echocardiography) 4 days after MI were 
included in the study, since it is established that an EF under 55 % is an indicator of 
heart damage. Animals were then divided into eight groups (n=5) as showed in Table 1.  
2.5.2 Intramyocardial administration of the microparticles 
One week after the LAD occlusion, MPs were intramyocardially administered using a 
29 gauge needle in four points surrounding the ischemic area, evidenced by the scar 
formation. Intramyocardially treated groups consisted of 0.6 or 1.6 mg of VEGF-MPs 
(0.85 µg/mg). For its administration, particles were dispersed in a sterile buffered 
solution composed of 0.1 % (w/v) carboxymethylcellulose, 0.8 % (w/v) polysorbate 80 
and 0.8 % (w/v) mannitol in PBS, pH 7.4. All animals received 80 µl total volume. 
After injection chest was closed and animals were allowed to recover.  
Intramyocardial injection is becoming one of the main routes of administration of 
growth factors and cells in acute myocardial infarction preclinical and clinical trials. 
This administration path allows local delivery of the treatment with a better dose control 
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and avoiding adverse effects resulted from the dissemination of the growth factor 
through the organism. Despite being more invasive than other routes, for the large 
animal models and for the clinical application sophisticated devices have been 
constructed (Sherman et al. 2006). With this intramyocardial catheter-based delivery 
systems open chest surgery is no longer necessary, and intramyocardial injection has 
become a less invasive technique with excellent safety profiles in the clinical trials 
2.5.3 Oral administration of the nanoparticles and commercial CoQ10  
Oral administration of the CoQ-NPs, NL-NPs or CoQ10 commercial formulation started 
24 h after LAD occlusion and continued every three days during the first month and 
subsequently switched to weekly once until the end of the study. Animals treated with 
the nanoparticulate or with the commercial CoQ10 received a 100 mg/kg dose every 
three days throughout the first month and the 200 mg/kg dose once per week up to three 
months. Animals treated with NL-NPs received the equivalent amount of NPs. For oral 
administration, freeze dried particles were dispersed in distilled water using a sonicator 
prior administration that was performed with an oral rigid dosing cannula.  
2.5.4 Ecochardiographical evaluation 
The Echocardiographic analysis was performed using a Vevo770 high-resolution 
ultrasound system (Visualsonics, Toronto, Canada) as previously described (Benavides-
Vallve C. et al., 2012) 
The left ventricular (LV) systolic function of the heart was evaluated by measuring the 
EF, calculated using the Simpson’s rule, from a parasternal long axis view and four 
parasternal short axis views at different levels of the LV. At the long axis view the left 
ventricle length was measured from the aortic annulus to the endocardial border at the 
apex level in both diastole and systole. At the parasternal short axis view, the 
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endocardium was traced at four different levels in both systole and diastole, to calculate 
the areas required to calculate the Simpson’s value. 
All measurements were performed offline using dedicated Vevo770 quantification 
software (Vevo 770 v. 3.0.0).  
2.5.5 Histological studies  
Three months after surgery animals were sacrificed and hearts were collected for 
subsequent histological analysis. Harvested hearts were fixed and sliced in three 4-mm-
thick segments from apex to base. The hearts were dehydrated and embedded in 
paraffin. Sections (5 µm) were cut from each slice.  
To quantify the small caliber vessel density and area, anti-caveolin-1α antibody (diluted 
1:50) was used as marker, and 2 peri-infarct and 2 intra-infarct images per section were 
analyzed. Secondary antibody was Alexa Fluor 488 goat conjugated anti-mouse IgG 
(diluted 1:100). Images were acquired using the Axio Cam MR3 video camera at 20× 
connected to the Zeiss Axio Imager M1 microscope equipped with epifluorescence 
optics. Digital images were analyzed using MatLab® software platform (Mathworks 
Inc., Natick, MA, USA).  
3 Statistical analysis 
Data are expressed as mean ± SEM. Student's t-test was used to analyze statistical 
significance. P-values corresponded to a two-tailed unpaired t-test for the group 
comparison. A p < 0.05 was considered statistically significant using Prism software 
(GraphPad software, San Diego, CA, USA). 
4 Results and discussion 
4.1 Preparation and characterization of Coenzyme Q10 encapsulated nanoparticles 
The procedure was highly reproducible and we were able to produce large quantities of 
CoQ10 containing nanoparticles. The key variation we made from the small scale batch 
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preparation was the homogenization duration which was increased to 30 min from 15 
min used for 50 mg batch size (Ratnam et al., 2011). The fresh CoQ10 containing 
particles were of 147±9 nm (fresh), however a slight increase in the size 156±9 nm was 
observed after centrifugation to separate the free CoQ10 and surfactant which is 
expected and this increase is due to aggregation upon centrifugation. However, freeze 
drying process did not affect the particle characteristics and remained same due to 
inclusion of cryoprotectant trehalose. The entrapment efficiency was found to be about 
70% of initial CoQ10 entrapment (~35 mg CoQ10/100 mg polymer). CoQ10 entrapped 
PLGA nanoparticles were proven efficacious in diabetic and renal hypertensive models 
by preventing the free radicals, inflammation and lipid abnormalities (Ankola et al. 
2007, Ratnam et al. 2008, Ratnam et al. 2011).  
4.2 VEGF Microparticle preparation and characterization 
The process led to uniform sized particles of about 4.89 μm with a VEGF content of 
0.85 µg/mg equivalent to 85% EE. Our previous studies suggest the size of the particles 
is within the range for intramyocardial administration with a 29G syringe (Formiga et 
al., 2010). Residual PVA associated with the MP preparation was less than 1% of the 
initial amount used and this concentration should not cause any adverse reactions either 
by local injections or oral/systemic administration (DeMerlis and Schoneker, 2003; 
Baker et al., 2012). There are reports suggesting very high doses in rats (daily doses of 
2,000-5,000 mg/kg) over a period of 90 days showed no adverse or toxicological effects 
(Kelly et al., 2003). 
In vitro release profile showed a burst effect with 58 % of protein released within the 
first 4 h followed by a more sustained release until the end of the study (Figure 1). This 
burst effect could be a typical phenomenon of surface bound protein or the protein in 
the exterior layers of the particles releasing at much quicker rate than that is in the inner 
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cores. PEGylated particles exhibit a greater burst effect than non PEGylated owing to 
their increased hydrophilicity of the polymer. Once the superficial layers of the protein 
are depleted a more sustained release of protein is observed which is controlled by the 
diffusion as well as the amount of the protein remaining in the particles. In vivo release 
is expected to be slower due, in part, to the presence of tissue surrounding the particles, 
instead of an aqueous medium. 
4.3  Bioactivity of encapsulated VEGF 
HUVEC cell assay demonstrates the proliferative activity of VEGF-MPs and is as 
effective as respective free protein (Figure 2). This study further confirms the integrity 
of the protein during the encapsulation process by TROMS®. 
4.4 In vivo experiments 
Animals were divided into eight groups (n=5) and followed up to three months. 
Echocardiographic functional results have been analyzed grouped in three different 
efficacy studies to facilitate interpretation of obtained data.  
4.4.1 CoQ10 loaded nanoparticle efficacy study 
The CoQ-NPs improved the heart function significantly as indicated by increased EF 
rates when compared to the commercial CoQ10 which showed results comparable to that 
of the untreated group (Figure 3A). The improved performance of CoQ-NPs can be 
attributed to their ability to improve their peroral bioavailability and sustain the release 
of the encapsulated CoQ10 over a period of time allowing dose reduction while 
maintaining the activity. Even though the commercial formulation used in this study is 
reported to exhibit improved peroral bioavailability (Chopra, 2001), it is just not enough 
in the system under the current dosage regimen to elicit any positive response, may be a 
daily dosing would have been better with commercial form. Even though a precise 
mechanism of action of CoQ10 in MI is not known, in general it is attributed to its 
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antioxidant nature, ability to minimize inflammation, improve endothelium function 
(Dai et al., 2011; Lee et al., 2012). We have previously reported the efficacy of CoQ-
NPs in other experimental models (Ankola et al., 2007; Ratnam et al., 2009) however a 
more systematic understanding is required on their therapeutic potential before much 
efforts are put in to prove the performance of these compounds that are in general high 
dose molecules and currently in use as supplements.   
4.4.2 VEGF loaded microparticle efficacy study 
We have studied two doses of VEGF to establish a dose response and the doses selected 
were based on the success from our previous study in a rat model of ischemic heart 
disease (Formiga et al., 2010). The animals receiving VEGF-MPs improved the heart 
function as indicated by the increase in EF however both low and high dose show same 
response, while the control group which received NL-MPs offered no protection (Figure 
3B).  
4.4.3 Combined therapy   
Though the individual treatments of CoQ10-NPs and VEGF-MPs resulted in significant 
improvement in the EF (Figure 3C) these two failed to offer synergism when 
administered together. Expected synergy between proangiogenic and antioxidant 
therapies mediated by VEGF and CoQ10 was not observed. Moreover, if we put together 
these results with those obtained with the VEGF-MPs alone it appears that CoQ10-NPs 
counteract benefits of VEGF therapy (Figure 3D).  
There is compelling evidence that CoQ10 is an independent predictor of mortality in 
chronic heart failure (Molyneux et al., 2008), while a recent study suggests the plasma 
concentrations of CoQ10 is not associated with lower risk of AMI (Naidoo et al., 2012). 
Unfortunately, molecules such as CoQ10 are used as supplements with no clear doses or 
plasma levels established to prevent/manage/treat any pathology. It is important at this 
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juncture that the inherent biopharmaceutical/physicochemical problems associated with 
such molecules are addressed by formulating them appropriately before we make 
substantial claims on their effectiveness or ineffectiveness (Kumar 2012). 
CoQ10 role in the angiogenic process has not been studied in depth. There are some 
published works that explore CoQ10 in the tumor angiogenesis. It has been suggested an 
antiangiogenic effect of this molecule in the new vessel formation mediated by a 
mechanism in which endogenous VEGF serum levels are reduced (Premkumar et al., 
2007, 2008). In our approach VEGF released from the particles in the damaged heart 
acts in cooperation with endogenous VEGF that is secreted by the cells after MI. An 
explanation to the results of this study will be that, on one side VEGF-MPs and CoQ-
NPs will be exerting its proangiogenic and cardioprotective action respectively, and on 
the other CoQ-NPs will be also act reducing VEGF endogenous levels, thus limiting 
angiogenesis. This result emphasizes how important the co-administration of non-
regulated actives can be in the effectiveness of the treatment of the patients. There is, 
therefore, a need to go into depth in the interactions of these micronutrients that need to 
be controlled when patients undergo treatment.  
4.4.4 Histological studies  
Animals receiving VEGF-MPs showed a statistically highly significant increase 
(p<0.0001) in the number of capillaries in the infarct and peri-infarct area when 
compared with the control group (Figure 4A). This difference was reduce in the group 
receiving VEGF-MPs and CoQ-NPs (p=0.015). This data are in accordance with the 
functional results that present the same standard, suggesting that CoQ-NPs are reducing 
the VEGF-MPs angiogenic effect. In relation with the vessel mean area we have proved 
that is significantly smaller in the VEGF-MPs & CoQ-NPs animal group (p=0.02), 
indicating that vessel development is more immature in this group (Figure 4B). Finally, 
 15
no differences in the total caveoline positive area were found between control group and 
VEGF-MPs group, but there were differences in the VEGF-MPs & CoQ-NPs group in 
which it was reduced (Figure 4C). 
Taking all these data into account we can conclude that VEGF-MPs promotes vessel 
development, but its angiogenic effect is reduced when it is concurrently administered 
with CoQ-NPs, resulting in less functional benefit. 
5 Conclusion 
In this work polymeric nanoparticles containing antioxidant molecule ubiquinone and 
stealth microparticles containing VEGF were prepared by two different methods, both 
of them leading to high encapsulation efficiency. These drug delivery systems were 
applied in an animal model of MI by different administration routes. Treatments 
resulted in an improvement of the EF of the animals when administered separately, 
suggesting that they can be effective systems to treat this disease. In the case of VEGF-
MPs an angiogenic process underlies this benefit, confirmed by the quantification of 
larger number of capillaries in the animal hearts. Treatment with the CoQ-NPs present 
several advantages based on its oral administration, more feasible and non-invasive for 
the patient, also with lower cost.  
However, when both particles were administered concurrently no significant benefit 
was observed, suggesting that in the dose regime employed in this study, there is a 
counteraction between them. Histological analysis confirms that small vessel density 
and size is reduced in those animals included in this group. Finally, results in this study 
emphasize the need for extra care when using supplements with standard therapeutic 
interventions.  
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Figure captions 
 
Figure 1. In vitro release profile of VEGF-MPs in PBS-pH7.4 at 37 ºC.  
 
Figure 2. Cell proliferation assay to assess the stability of encapsulated VEGF. Free 
VEGF and VEGF-MPs are equally googl in their cell proliferation ability and are 
significant when compared to untreated control (***p<0.0001) 
 
Figure 3. Ejection fraction (cardiac function) observed in different groups: (A) CoQ-
NPs (B) VEGF-MPs (C) VEGF-MPs and CoQ-NPs combination and (D) Summary of 
individual and combination VEGF treatments. EF was assessed by echocardiography 
before and 3 months after treatment and mean improvement±SD is represented.  
 
Figure 4. The histological section were imaged and quantified for the analysis of (A) 
Vessel density (B) Average vessel diameter and (c) Total caveoline positive area. Small 
vessels were stained using anti-caveoline-1α antibody.  
 
Table captions 
Table 1. Animals were divided in eight different groups (n=5 / group). Three efficacy 
studies were performed to observe effects of CoQ-NPs, VEGF-MPs and combination of 
both.  
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